WO2008069688A3 - Methods for treating inflammatory disease by administering aldehydes and derivatives thereof - Google Patents

Methods for treating inflammatory disease by administering aldehydes and derivatives thereof Download PDF

Info

Publication number
WO2008069688A3
WO2008069688A3 PCT/PT2007/000009 PT2007000009W WO2008069688A3 WO 2008069688 A3 WO2008069688 A3 WO 2008069688A3 PT 2007000009 W PT2007000009 W PT 2007000009W WO 2008069688 A3 WO2008069688 A3 WO 2008069688A3
Authority
WO
WIPO (PCT)
Prior art keywords
administering
inflammatory disease
aldehydes
derivatives
methods
Prior art date
Application number
PCT/PT2007/000009
Other languages
French (fr)
Other versions
WO2008069688A2 (en
Inventor
Carlos C Romao
Marta Norton De Matos
Original Assignee
Alfama Investigacao E Desenvol
Carlos C Romao
Marta Norton De Matos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfama Investigacao E Desenvol, Carlos C Romao, Marta Norton De Matos filed Critical Alfama Investigacao E Desenvol
Priority to AU2007328549A priority Critical patent/AU2007328549A1/en
Priority to EP07709271A priority patent/EP2099439A2/en
Publication of WO2008069688A2 publication Critical patent/WO2008069688A2/en
Publication of WO2008069688A3 publication Critical patent/WO2008069688A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method is disclosed for treating inflammatory disease in an animal in need thereof by administering to the animal a pharmaceutical composition containing an anti-inflammatory effective amount of an organic aldehyde compound or a derivative thereof in a pharmaceutically acceptable vehicle.
PCT/PT2007/000009 2006-12-06 2007-02-06 Methods for treating inflammatory disease by administering aldehydes and derivatives thereof WO2008069688A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2007328549A AU2007328549A1 (en) 2006-12-06 2007-02-06 Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP07709271A EP2099439A2 (en) 2006-12-06 2007-02-06 Methods for treating inflammatory disease by administering aldehydes and derivatives thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87315506P 2006-12-06 2006-12-06
US60/873,155 2006-12-06

Publications (2)

Publication Number Publication Date
WO2008069688A2 WO2008069688A2 (en) 2008-06-12
WO2008069688A3 true WO2008069688A3 (en) 2008-07-31

Family

ID=38066608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PT2007/000009 WO2008069688A2 (en) 2006-12-06 2007-02-06 Methods for treating inflammatory disease by administering aldehydes and derivatives thereof

Country Status (3)

Country Link
EP (1) EP2099439A2 (en)
AU (1) AU2007328549A1 (en)
WO (1) WO2008069688A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
WO2003066067A2 (en) 2002-02-04 2003-08-14 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US7968605B2 (en) 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
JP2010525055A (en) * 2007-04-24 2010-07-22 アルファーマ−インベスティガシオ エ デセンボルビメント デ プロデュトス ファルマセウティコス エレデア． Treatment of infection with carbon monoxide
ES2656237T3 (en) 2011-04-19 2018-02-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
ES2628634T3 (en) 2011-07-21 2017-08-03 Alfama, Inc. Carbon monoxide-ruthenium releasing molecules and uses thereof
US9932315B2 (en) 2014-08-08 2018-04-03 Massachusetts Institute Of Technology Persistent carbene adducts and related methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092075A2 (en) * 2001-05-15 2002-11-21 Northwick Park Institute For Medical Research Therapeutic delivery of carbon monoxide
WO2003066067A2 (en) * 2002-02-04 2003-08-14 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
WO2003094932A1 (en) * 2002-05-09 2003-11-20 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20040228930A1 (en) * 2002-11-07 2004-11-18 Billiar Timothy R. Treatment for hemorrhagic shock

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092075A2 (en) * 2001-05-15 2002-11-21 Northwick Park Institute For Medical Research Therapeutic delivery of carbon monoxide
WO2003066067A2 (en) * 2002-02-04 2003-08-14 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
WO2003094932A1 (en) * 2002-05-09 2003-11-20 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20040228930A1 (en) * 2002-11-07 2004-11-18 Billiar Timothy R. Treatment for hemorrhagic shock

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OTTERBEIN L E ET AL: "Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 4, April 2000 (2000-04-01), pages 422 - 428, XP002249546, ISSN: 1078-8956 *
OTTERBEIN L E: "Carbon monoxide: innovative anti-inflammatory properties of an age-old gas molecule", ANTIOXIDANTS AND REDOX SIGNALING, MARY ANN LIEBERT, LARCHMONT, NY, US, vol. 4, no. 2, April 2002 (2002-04-01), pages 309 - 319, XP009068341, ISSN: 1523-0864 *

Also Published As

Publication number Publication date
WO2008069688A2 (en) 2008-06-12
AU2007328549A1 (en) 2008-06-12
EP2099439A2 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
WO2008069688A3 (en) Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
NL300929I2 (en) Telotristat, optionally in the form of a pharmaceutically acceptable ester or salt, in particular telotristat ethyl, more in particular the hippurate salt of telotristat ethyl
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
WO2007130429A3 (en) Histone deacetylase and tubulin deacetylase inhibitors
DE602005013793D1 (en) THIAZONE DERIVATIVES WITH VAP-1-HEMMENDER EFFECT
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
WO2006124413A3 (en) Methods for treating drug resistant cancer
MX2010003603A (en) Method of treating polycystic kidney diseases with ceramide derivatives.
WO2006088814A3 (en) Dosage form and method for sustained release of a substituted pyrazine compound
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
WO2007098964A3 (en) Pyrrazole derivatives as sigma receptors antagonists
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
AR057904A1 (en) MEDICATIONS THAT INCLUDE AN ANTIMUSCERINIC AGENT AND A CORTICOESTEROID
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2008000421A3 (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
EA200870224A1 (en) BENZO [F] IZININDOL-2-ILPHENYL ACID ACETIC DERIVATIVES AS AN AGONISTS EP EP RECEPTORS
WO2009155070A3 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
AR063469A1 (en) POLYMORPHIC FORMS OF ACID (3R, 5R) -7- [2- (4-FLUOROPHENYL) -5-ISOPROPIL-3-PHENYL-4 - [(4-HYDROXYMETHYLAMINE) CARBON]] -PIRROL-1-IL] -3, 5 -DIHIDROXI-HEPTANOICO, HEMICALCIO SALT, METHODS OF PREPARATION OF THE SAME, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND ITS USE IN THE TREATMENT OF DISEASES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07709271

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007328549

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007709271

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007328549

Country of ref document: AU

Date of ref document: 20070206

Kind code of ref document: A